Q BioMed Inc. (QBIO)

USD 0.0

(0.0%)

Market Cap (In USD)

29.01 Thousand

Revenue (In USD)

284.35 Thousand

Net Income (In USD)

-2.05 Million

Avg. Volume

17.06 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.0E-5-0.0405
PE
-0.01
EPS
-0.02
Beta Value
82.285
ISIN
US74736N1054
CUSIP
74736N105
CIK
1596062
Shares
145095000.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Denis D. Corin
Employee Count
-
Website
https://www.qbiomed.com
Ipo Date
2015-06-17
Details
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.